Trial NCT04683484
Publication Nguyen T, Lancet, 2022
Primary outcome on the report: Number and percentage of participants with solicited local and systemic adverse events occurred within 7 days after vaccination and laboratory results (serum biochemistry and hematology) at days 0, 7, 28, 35 according to FDA toxicity scoring; anti-S IgG responses to Nanocovax evaluated by chemiluminescence immunoassay (CLIA)

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.